Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/158947
Title: The Implication of the Brain Insulin Receptor in Late Onset Alzheimer's Disease Dementia
Author: Folch, Jaume
Ettcheto Arriola, Miren
Busquets Figueras, Oriol
Sánchez-López, E. (Elena)
Castro Torres, Ruben Dario
Verdaguer Cardona, Ester
Manzine, Patricia
Rabiei Poor, Saghar
García López, María Luisa
Olloquequi González, Jordi
Beas-Zarate, Carlos
Auladell i Costa, M. Carme
Camins Espuny, Antoni
Keywords: Malaltia d'Alzheimer
Malalties neurodegeneratives
Diabetis no-insulinodependent
Etiologia
Resistència a la insulina
Alzheimer's disease
Neurodegenerative Diseases
Non-insulin-dependent diabetes
Etiology
Insulin resistance
Issue Date: 29-Jan-2018
Publisher: MDPI
Abstract: Alzheimer's disease (AD) is progressive neurodegenerative disorder characterized by brain accumulation of the amyloid β peptide (Aβ), which form senile plaques, neurofibrillary tangles (NFT) and, eventually, neurodegeneration and cognitive impairment. Interestingly, epidemiological studies have described a relationship between type 2 diabetes mellitus (T2DM) and this pathology, being one of the risk factors for the development of AD pathogenesis. Information as it is, it would point out that, impairment in insulin signalling and glucose metabolism, in central as well as peripheral systems, would be one of the reasons for the cognitive decline. Brain insulin resistance, also known as Type 3 diabetes, leads to the increase of Aβ production and TAU phosphorylation, mitochondrial dysfunction, oxidative stress, protein misfolding, and cognitive impairment, which are all hallmarks of AD. Moreover, given the complexity of interlocking mechanisms found in late onset AD (LOAD) pathogenesis, more data is being obtained. Recent evidence showed that Aβ42 generated in the brain would impact negatively on the hypothalamus, accelerating the 'peripheral' symptomatology of AD. In this situation, Aβ42 production would induce hypothalamic dysfunction that would favour peripheral hyperglycaemia due to down regulation of the liver insulin receptor. The objective of this review is to discuss the existing evidence supporting the concept that brain insulin resistance and altered glucose metabolism play an important role in pathogenesis of LOAD. Furthermore, we discuss AD treatment approaches targeting insulin signalling using anti-diabetic drugs and mTOR inhibitors.
Note: Reproducció del document publicat a: https://doi.org/10.3390/ph11010011
It is part of: Pharmaceuticals, 2018, vol. 11, num. 1, p. 11
URI: http://hdl.handle.net/2445/158947
Related resource: https://doi.org/10.3390/ph11010011
ISSN: 1424-8247
Appears in Collections:Articles publicats en revistes (Farmacologia, Toxicologia i Química Terapèutica)
Articles publicats en revistes (Biologia Cel·lular, Fisiologia i Immunologia)
Articles publicats en revistes (Farmàcia, Tecnologia Farmacèutica i Fisicoquímica)

Files in This Item:
File Description SizeFormat 
676264.pdf920.32 kBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons